In view of the emergence and frequency of multidrug-resistant and extensively drug-resistant tuberculosis and consequences of acquired resistance to clinically used drugs, we undertook the design and synthesis of novel prototypes that possess the advantage of the two pharmacophores of thiourea and 1,3,4-thiadiazole in a single molecular backbone. Three compounds from our series were distinguished from the others by their promising activity profiles against Mycobacterium tuberculosis strain H37Rv. Compounds 11 and 19 were the most active representatives with minimum inhibitory concentration (MIC) values of 10.96 and 11.48 µM, respectively. Compound 15 was shown to inhibit M. tuberculosis strain H37Rv with an MIC value of 17.81 µM. Cytotoxicity results in the Vero cell line showed that these three derivatives had selectivity indices between 1.8 and 8.7. In order to rationalize the biological results of our compounds, molecular docking studies with the enoyl acyl carrier protein reductase (InhA) of M. tuberculosis were performed and compounds 11, 15, and 19 were found to have good docking scores in the range of −7.12 to −7.83 kcal/mol.
考虑到多药耐药和广泛耐药结核病的出现和频率,以及对临床使用药物获得性耐药的后果,我们进行了新型原型药物的设计和合成,这些药物在一个分子骨架上同时具有
硫脲和1,3,4-
噻二唑两种药效基团的优势。在我们的系列化合物中,有三种化合物因其对结核分枝杆菌H37Rv株的潜在活性特征而脱颖而出。化合物11和19是最具活性的代表,其最小抑制浓度(MIC)值分别为10.96和11.48微摩尔。化合物15显示对结核分枝杆菌H37Rv株的MIC值为17.81微摩尔。在Vero
细胞系中的细胞毒性结果显示,这三种衍
生物的选择性指数在1.8至8.7之间。为了合理化我们化合物的
生物学结果,我们进行了分子对接研究,与结核分枝杆菌的烯酰载体蛋白还原酶(InhA)结合,发现化合物11、15和19的对接得分在-7.12至-7.83千卡/摩尔的范围内。